SLC38A5

Across TCGA pan-cancer cohorts, SLC38A5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC38A5 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLC38A5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC38A5 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where SLC38A5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.221	0.534	.004	14	view →
LUAD	DFS	Median	II,III,IV	0.784	0.283	<.001	11	view →
LSCC	OS	Quartile	II,III,IV	0.638	0.996	.027	8	view →
HNSC	DFS	Quartile	All	0.901	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC38A5–GBM (DFS)

Open the GBM breakdown →